Total and cancer mortality after supplementation with vitamins and minerals: Follow-up of the linxian general population nutrition intervention trial

Journal of the National Cancer Institute

Volumn 101, Issue 7, 2009, Pages 507-518

  Qiao, You Lin ^a   Dawsey, Sanford M ^b   Kamangar, Farin ^b   Fan, Jin Hu ^a   Abnet, Christian C ^b   Sun, Xiu Di ^a   Johnson, Laura Lee ^c   Gail, Mitchell H ^b   Dong, Zhi Wei ^a   Yu, Binbing ^d   Mark, Steven D ^b   Taylor, Philip R ^b  

^a CANCER HOSPITAL   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; MOLYBDENUM; NICOTINIC ACID; PLACEBO; RETINOL PALMITATE; RIBOFLAVIN; SELENIUM; ZINC OXIDE; ANTIOXIDANT; DRUG DERIVATIVE; RETINOL; TRACE ELEMENT; VITAMIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PREVENTION; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STOMACH CANCER; STROKE; TREATMENT WITHDRAWAL; VITAMIN SUPPLEMENTATION; AGE; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; EPIDEMIOLOGY; KAPLAN MEIER METHOD; MALNUTRITION; MIDDLE AGED; MORTALITY; NEOPLASM; RANDOMIZED CONTROLLED TRIAL; RISK; RISK FACTOR;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALPHA-TOCOPHEROL; ANTIOXIDANTS; ASCORBIC ACID; BETA CAROTENE; CHINA; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIETARY SUPPLEMENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MALNUTRITION; MICRONUTRIENTS; MIDDLE AGED; MOLYBDENUM; NEOPLASMS; NIACIN; ODDS RATIO; RIBOFLAVIN; RISK FACTORS; SELENIUM; VITAMIN A; VITAMINS; ZINC OXIDE;

EID: 63649142337     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp037     Document Type: Article

References (50)

1. Li JY, Liu BQ, Li GY, Chen ZJ, Sun XI, Rong SD. Atlas of cancer mortality in the People's Republic of China. An aid for cancer control and research. Int J Epidemiol. 1981;10(2):127-133.
2. Li JY. Epidemiology of esophageal cancer in China. J Natl Cancer Inst Monogr. 1982;62:113-120.
3. Yang CS, Sun Y, Yang QU, et al. Vitamin A and other deficiencies in Linxian, a high esophageal cancer incidence area in northern China. J Natl Cancer Inst. 1984;73(6):1449-1153.
4. Li B, Taylor PR, Li JY, et al. Linxian nutrition intervention trials. Design, methods, participant characteristics, and compliance. Ann Epidemiol. 1993;3(6):577-585.
5. Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst. 1993;85(18):1483-1492.
6. Tran GD, Sun XD, Abnet CC, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. IntJ Cancer. 2005;113(3)456-463.
7. Liu SF, Shen Q, Dawsey SM, et al. Esophageal balloon cytology and subsequent risk of esophageal and gastric-cardia cancer in a high-risk Chinese population. Int J Cancer. 1994;57(6):775-780.
8. McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials: a systematic review. JAMA. 2003;289(19):2545-2553.
9. Blot WJ, LiJY, Taylor PR, Guo W, Dawsey SM, Li B. The Linxian trials: mortality rates by vitamin-mineral intervention group. Am J Clin Nutr. 1995;62:1424S-1426S.
10. Qu CX, Kamangar F, Fan JH, et al. Chemoprevention of primary liver cancer: a randomized, double-blind trial in Linxian, China. J Natl Cancer Inst. 2007;99(16):1240-1247.
11. Gray RJ. A class of K-sample test for comparing cumulative incidence of competing risk. Ann Stat. 1988;16:1141-1154.
12. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of competing risk. J Am Stat Assoc. 1999;94:496-509.
13. Mark SD, Qiao YL, Dawsey SM, et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. J Natl Cancer Inst. 2000;92(21):1753-1763.
14. Taylor PR, Qiao YL, Abnet CC, et al. Prospective study of serum vitamin E levels and esophageal and gastric cancers. J Natl Cancer Inst. 2003;95(18):1414-1416.
15. Abnet CC, Qiao YL, Dawsey SM, et al. Prospective study of serum retinol, beta-carotene, beta-cryptoxanthin, and lutein/zeaxanthin and esophageal and gastric cancers in China. Cancer Causes Control. 2003;14(7):645-655.
16. Wei W, Abnet CC, Qiao YL, et al. Prospective study of serum selenium concentration and esophageal and gastric cardia cancer, heart disease, stroke, and total death. Am J Clin Nutr. 2004;79(1):80-85.
17. Limburg PJ, Wei W, Ahnen DJ, et al. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology. 2005;129(3):863-873.
18. Abnet CC, Lai B, Qiao YL, et al. Zinc concentration in esophageal biopsy specimens measured by x-ray fluorescence and esophageal cancer risk. J Natl Cancer Inst. 2005;97(4):301-306.
19. Mark SD, Wang W, Fraumeni JF Jr, et al. Do nutritional supplements lower the risk of stroke or hypertension? Epidemiology. 1998;9(1):9-15.
20. Mirvish SS. Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. Cancer Lett. 1995;93(1):17-48.
21. Jenab M, Riboli E, Ferrari P, et al. Plasma and dietary vitamin C levels and risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Carcinogenesis. 2006;27(11):2250-2257.
22. Simon JA, Hudes ES, Browner WS. Serum ascorbic acid and cardiovascular disease prevalence in U.S. adults. Epidemiology. 1998;9(3):316-321.
23. Yokoyama T, Date C, Kokubo Y, Yoshiike N, Matsumura Y, Tanaka H. Serum vitamin C concentration was inversely associated with subsequent 20-year incidence of stroke in a Japanese rural community. The Shibata study. Stroke. 2000;31(10):2287-2294.
24. Kurl S, Tuomainen TP, Laukkanen JA, et al. Plasma vitamin C modifies the association between hypertension and risk of stroke. Stroke. 2002;33(6):1568-1573.
25. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002; 288(19):2432-2440.
26. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individualsa randomised placebo-controlled trial. Lancet. 2002;360(9325):23-33.
27. Peto R, Doll R, Buckley JD, Sporn MB. Can dietary beta-carotene materially reduce human cancer rates? Nature. 1981;290(5803):201-208.
28. The ATBC Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-TocopherolBeta Carotene Cancer Prevention Study Group. N Engl J Med. 1994;330(15):1029-1035.
29. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334(18):1150-1155.
30. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334(18):1145-1149.
31. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294(1):56-65.
32. Taylor PR. Prevention of gastric cancer: a miss. J Natl Cancer Inst. 2007;99(2):101-103.
33. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297(8):842-857.
34. Yu SY, Zhu YJ, Li WG, et al. A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China. Biol Trace Elem Res. 1991;29(3):289-294.
35. Yu SY, Zhu YJ, Li WG. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol Trace Elem Res. 1997;56(1):117-124.
36. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJUInt. 2003;91(7):608-612.
37. Zou XN, Taylor PR, Mark SD, et al. Seasonal variation of food consumption and selected nutrient intake in Linxian, a high risk area for esophageal cancer in China. Int J Vitam Nutr Res. 2002;72(6):375-382.
38. Li JY, Taylor PR, Li B, et al. Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst. 1993;85(18):1492-1498.
39. Duffield-Lillico AJ, Reid ME, Turnbull BW, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev. 2002;11(7):630-639.
40. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst. 1996;88(21):1550-1559.
41. Albanes D, Heinonen OP, Taylor PR, et al. Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study: effects of base-line characteristics and study compliance. J Natl Cancer Inst. 1996;88(21):1560-1570.
42. VirtamoJ, Pietinen P, Huttunen JK, et al. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA. 2003;290(4)476-485.
43. Leppala JM, Virtamo J, Fogelholm R, et al. Controlled trial of alphatocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vase Biol. 2000;20(1):230-235.
44. Tornwall ME, Virtamo J, Korhonen PA, Virtanen MJ, Albanes D, Huttunen JK. Postintervention effect of alpha tocopherol and beta carotene on different strokes: a 6-year follow-up of the Alpha Tocopherol, Beta Carotene Cancer Prevention Study. Stroke. 2004;35(8):1908-1913.
45. Goodman GE, Thornquist MD, Balmes J, et al. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst. 2004;96(23):1743-1750.
46. Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med. 1999;340(2):101-107.
47. Grau MV, Baron JA, Sandler RS, et al. Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial. J Natl Cancer Inst. 2007;99(2):129-136.
48. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652-1662.
49. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99(4):272-282.
50. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99(4):283-290.